Chembio Diagnostics, Inc.
3661 Horseblock Road
Medford
New York
11763
United States
Tel: 631-924-1135
Fax: 631-924-6033
Website: http://www.chembio.com/
Email: info@chembio.com
252 articles about Chembio Diagnostics, Inc.
-
Qualigen Therapeutics Divests FastPack® Diagnostics Business
7/24/2023
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that it has sold its FastPack ® diagnostics business to Chembio Diagnostics, Inc.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
-
Chembio Diagnostics Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher Scientific’s Healthcare Channel
5/18/2020
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has signed a multi-year, non‑exclusive agreement with Thermo Fisher Scientific’s healthcare channel, to distribute Chembio’s DPP COVID-19 System in the United States.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
-
Chembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial Results
2/9/2018
The Company expects shipments to begin during the second quarter of 2018.
-
Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP HIV-Syphilis System
12/21/2017
The Company plans to file a PMA submission with the FDA during the first quarter of 2018 to support commercialization of the first POC HIV-Syphilis assay in the U.S.
-
Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test
12/19/2017
Under terms of the 18-month agreement, Chembio will receive up to $2.9M in funding from Astra.
-
Chembio Receives $8.5M Commitment From Bio-Manguinhos to Purchase Components for Production of DPP Assays in Brazil During 2018
12/5/2017
Chembio received payments of $4.2 million of accounts receivable balances from Bio-Manguinhos.
-
Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care DPP Zika Assays and DPP Micro Readers
11/28/2017
The UNICEF LTA, which is valid through December 31, 2019, includes a firm purchase commitment of $1.5 million and possible additional purchases of up to $3.4 million, for a potential total amount of up to $4.9 million.
-
Chembio Diagnostics Reports Third Quarter 2017 Financial Results
11/9/2017
Total revenues of $7.6 million, compared with $3.7 million (an increase of 102.5%).
-
Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results
11/1/2017
The CEO and CFO will host a conference call and webcast at 4:30 p.m. ET on November 8, 2017 to discuss these results.
-
Chembio Announces Return Of President And CEO John Sperzel
10/2/2017
-
Chembio Receives FDA Emergency Use Authorization For The First Rapid Zika IgM Test
9/28/2017
-
Chembio Announces Retirement Of Chief Financial Officer
8/18/2017
-
Chembio Reports Second Quarter 2017 Financial Results
8/10/2017
-
Chembio To Host Conference Call To Discuss Second Quarter 2017 Financial Results
8/3/2017
-
Gail S. Page Joins Chembio Board of Directors
7/6/2017
-
Chembio’s DPP Zika System Including The DPP Micro Reader Approved By Brazil’s Health Regulatory Agency
7/5/2017
-
Chembio Announces At-The-Market Program
6/28/2017